BioCentury
ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

December 5, 2011 8:00 AM UTC

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) was up $3.11 to $66.98 last week after the EC approved an MAA to expand the label of Soliris eculizumab to include treatment of atypical hemolytic uremic syndrome (aHUS), a rare and chronic blood disease that can lead to renal failure. Solaris is approved for aHUS in the U.S. and for paroxysmal nocturnal hemoglobinuria in the EU and U.S.

Amarin Corp. plc (NASDAQ:AMRN) gained $0.68 (10%) to $7.78 last week after FDA accepted for review an NDA for AMR101 to treat hypertriglyceridemia in patients with triglyceride levels of 500 mg/dL or greater. The PDUFA date is July 26...